Iph4102-201
Web14 mrt. 2024 · Biological: IPH4102 Study Type Interventional Enrollment (Anticipated) 166 Phase Phase 2 Contacts and Locations This section provides the contact details for … WebInterpretation IPH4102 is safe and shows encouraging clinical activity in patients with relapsed or refractory cutaneous T-cell lymphoma, particularly those with Sézary syndrome. If confirmed in future trials, IPH4102 could become a novel treatment option for these patients. A multi-cohort, phase 2 trial (TELLOMAK) is underway to confirm
Iph4102-201
Did you know?
Web29 nov. 2024 · Aims: Sezary Syndrome (SS) is the most aggressive form of cutaneous T cell lymphoma (CTCL), characterized with high blood involvement and expression o… WebInnate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announced that the design of the “TELLOMAK” Phase II trial and new preclinical data supporting the potential of IPH4102 in peripheral T-cell lymphoma (“PTCL”) as well as Adult T-cell leukemia/lymphoma (“ATLL”) will be presented at the International Conference on …
Web13 okt. 2016 · IPH4102 is a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody, designed to trigger killing of CTCL cancer cells, an orphan disease. This group of rare cutaneous lymphomas of T...
WebRELATED APPLICATIONS. This application claims priority to U.S. Provisional Application No. 63/221,595 filed on Jul. 14, 2024, the content of which is hereby incorporated in its en Web29 jan. 2024 · Innate Pharma : RECEIVES FDA FAST TRACK DESIGNATION FOR IPH4102 IN RELAPSED OR REFRACTORY SÉZARY SYNDROME MarketScreener INNATE PHARMA RECEIVES FDA FAST TRACK DESIGNATION FOR IPH4102 IN RELAPSED OR REFRACTORY SÉZARY SYNDROME Fast Track designation is …
WebIPH4102 is a humanised, first-in-class, monoclonal antibody that is designed to deplete KIR3DL2-expressing cells via antibody-dependent cell cytotoxicity and phago-cytosis.11 …
WebProtocol: IPH4102-201: TELLOMAK: An open label, multi-cohort, multi-center phase II study evaluating the efficacy and safety of IPH4102 alone or in combination with chemotherapy in patients with Advanced T-cell lymphoma Zhou, A. Medpace Clinical Research LLC, Innate Pharma SA 4/12/22 → 4/12/25 Project: Research project eastern michigan environmental scienceWeb3 dec. 2024 · innate pharma announces updated results that support advancement of iph4102 in refractory sÉzary syndrome at the american society of hematology 2024 annual meeting differentiating... march 26, 2024 cu housing and dining servicesWeb25 jun. 2024 · IPH4102 is a humanised, first-in-class, monoclonal antibody that targets KIR3DL2, a cell surface protein widely expressed in cutaneous T-cell lymphoma, and … cuh outlook emailWeb12 jul. 2024 · IPH4102, a monoclonal antibody directed against the immune receptor molecule KIR3DL2, for the treatment of cutaneous T-cell lymphoma Carrie Van Der … cuh palliative care referral formWebArms in the two indications will consist of two cohorts each and will investigate IPH4102 in KIR3DL2 expressing and non-expressing patients. The trial’s primary endpoint is objective response rate and key secondary measures include treatment emergent adverse events, quality of life, overall response rate, progression-free survival, and overall survival. cuh parking servicesWebStudy of IPH4102 alone or in combination with chemotherapy in patients with Advanced T-cell Lymphoma. A.4.1 Sponsor's protocol code number IPH4102-201 A.5.2 US NCT … eastern michigan football 2021WebBrief Title: IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma Official Title: TELLOMAK: T-cell Lymphoma Anti- KIR3DL2 Therapy . … eastern michigan fb score